Literature DB >> 23031553

Melanoma of unknown primary origin: a population-based study in the Netherlands.

Anne C de Waal1, Katja K H Aben, Michelle M van Rossum, Lambertus A L M Kiemeney.   

Abstract

AIM: Few population-based studies have been published on melanoma of unknown primary origin (MUP). This study's aim is to describe characteristics and survival of MUP patients in the Netherlands, based on nationwide data from the Netherlands Cancer Registry (NCR).
METHODS: Patient and tumour characteristics of MUP patients were retrieved from the NCR. Subgroups were made according to metastatic site: nodal or distant. Survival rates were calculated using the Kaplan-Meier method. To obtain a better insight in the composition and prognosis of the MUP group, the survival was compared to that of patients with melanoma of a known primary origin (MKP), tumour-node-metastasis (TNM) stage III and IV.
RESULTS: Of all 33,181 melanoma patients diagnosed between 2003 and 2009, 2.6% (n=857) were diagnosed with MUP. MUP patients with nodal metastases had a similar survival as MKP stage III with macroscopic nodal involvement. After stratification according to the number of involved lymph nodes, the survival of patients with nodal metastases with one involved lymph node was not significantly different between MUP and MKP. The survival of MUP patients with two or more involved lymph nodes was slightly worse than that of MKP stage III patients with macroscopic nodal involvement with two or more involved lymph nodes. MUP patients with distant metastases had a similar survival as MKP stage IV. After stratification according to number of metastatic sites and metastatic site category, the survival in MKP stage IV patients with (sub)cutaneous metastases was slightly worse than MUP distant patients with (sub)cutaneous metastases.
CONCLUSIONS: The results of this study imply that MUP patients form a heterogeneous group, and that MUP patients with nodal metastases could be classified as stage III melanoma with macroscopic nodal involvement, and MUP patients with distant metastases as stage IV melanoma.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23031553     DOI: 10.1016/j.ejca.2012.09.005

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  18 in total

1.  Multidisciplinary Care for Melanoma of Unknown Primary: Experience in the Era of Molecular Profiling.

Authors:  James P De Andrade; Paul Wong; Michael P O'Leary; Vishwas Parekh; Arya Amini; Hans F Schoellhammer; Kim A Margolin; Michelle Afkhami; Laleh G Melstrom
Journal:  Ann Surg Oncol       Date:  2020-09-09       Impact factor: 5.344

2.  Utility of sentinel lymph node biopsy for solitary dermal melanomas.

Authors:  Yinin Hu; Puja Shah; George J Stukenborg; Craig L Slingluff
Journal:  J Surg Oncol       Date:  2015-02-24       Impact factor: 3.454

3.  Clinicopathological Features, Staging, and Current Approaches to Treatment in High-Risk Resectable Melanoma.

Authors:  Emily Z Keung; Jeffrey E Gershenwald
Journal:  J Natl Cancer Inst       Date:  2020-09-01       Impact factor: 13.506

4.  Stage IV melanoma of unknown primary: A population-based study in the United States from 1973 to 2014.

Authors:  Jeffrey F Scott; Ruzica Z Conic; Cheryl L Thompson; Meg R Gerstenblith; Jeremy S Bordeaux
Journal:  J Am Acad Dermatol       Date:  2018-03-23       Impact factor: 11.527

5.  Aggressive behaviour of metastatic melanoma in a patient with neurofibromatosis type 1.

Authors:  Robert W Foley; Robert M Maweni; Aurelie Fabre; David G Healy
Journal:  Case Rep Surg       Date:  2015-03-29

6.  Metastatic malignant melanoma of the inguinal lymph node with unknown primary lesion.

Authors:  Sherif Ali Eltawansy; Ryane Panasiti; Samaa Hasanien; Dennis Lourdusamy; David Sharon
Journal:  Case Rep Med       Date:  2015-02-01

7.  Molecular characterization and patient outcome of melanoma nodal metastases and an unknown primary site.

Authors:  Aleksandra Gos; Monika Jurkowska; Alexander van Akkooi; Caroline Robert; Hanna Kosela-Paterczyk; Senada Koljenović; Nyam Kamsukom; Wanda Michej; Arkadiusz Jeziorski; Piotr Pluta; Cornelis Verhoef; Janusz A Siedlecki; Alexander M M Eggermont; Piotr Rutkowski
Journal:  Ann Surg Oncol       Date:  2014-05-28       Impact factor: 5.344

8.  A Solitary Melanoma Metastasis Confined to the Submandibular Gland.

Authors:  Senne Gorris; Celia Perdaens; Veerle Delvaux; Vincent Vander Poorten; Bart Neyns; Ilan Baron
Journal:  Case Rep Oncol       Date:  2021-06-18

9.  Treatment of Regional Metastatic Melanoma of Unknown Primary Origin.

Authors:  Elke J A H van Beek; Alfons J M Balm; Omgo E Nieweg; Olga Hamming-Vrieze; Peter J F M Lohuis; W Martin C Klop
Journal:  Cancers (Basel)       Date:  2015-08-10       Impact factor: 6.639

10.  Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma.

Authors:  Lisa Zimmer; Thomas K Eigentler; Felix Kiecker; Jan Simon; Jochen Utikal; Peter Mohr; Carola Berking; Eckhart Kämpgen; Edgar Dippel; Rudolf Stadler; Axel Hauschild; Michael Fluck; Patrick Terheyden; Rainer Rompel; Carmen Loquai; Zeinab Assi; Claus Garbe; Dirk Schadendorf
Journal:  J Transl Med       Date:  2015-11-06       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.